Agenus Inc., of Lexington, Mass., said the first patient was dosed in a phase I trial of AGEN1884, an anti-CTLA-4 checkpoint antibody. The study in patients with advanced or refractory cancer is designed to evaluate the safety of AGEN1884 and determine the estimated maximum tolerated dose.